Cadmium - A metallohormone?

Toxicology and Applied Pharmacology

Volumn 238, Issue 3, 2009, Pages 266-271

  Byrne, Celia ^a   Divekar, Shailaja D ^a   Storchan, Geoffrey B ^a   Parodi, Daniela A ^a   Martin, Mary Beth ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Cadmium; Endocrine disruptor

Indexed keywords

ANDROGEN RECEPTOR; CADMIUM; DRINKING WATER; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICKEL; NUCLEAR RECEPTOR COACTIVATOR 2; PROGESTERONE RECEPTOR; PROTEIN KINASE B; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3;

BREAST CANCER; CADMIUM POISONING; CANCER INCIDENCE; CANCER RISK; CARCINOGENICITY; CIGARETTE SMOKING; DIET; ENVIRONMENTAL EXPOSURE; ESTROGEN ACTIVITY; HORMONE ACTION; HUMAN; NONHUMAN; OCCUPATIONAL EXPOSURE; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR;

ANDROGENS; ANIMALS; BINDING SITES; CADMIUM; ENDOCRINE DISRUPTORS; ENVIRONMENTAL POLLUTANTS; ESTROGENS; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PROTEIN CONFORMATION; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67649662232     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.03.025     Document Type: Review

References (78)

1. Akesson A., Julin B., and Wolk A. Long-term dietary cadmium intake and postmenopausal endometrial cancer incidence: a population-based prospective cohort study. Cancer Res. 68 (2008) 6435-6441
2. Althuis M.D., Dozier J.M., Anderson W.F., Devesa S.S., and Brinton L.A. Global trends in breast cancer incidence and mortality 1973-1997. Int. J. Epidemiol. 34 (2005) 405-412
3. Bako G., Smith E.S.O., Hanson J., and Dewar R. The geographical distribution of high cadmium concentrations in the environment and prostate cancer in Alberta. Can. J. Public Health 73 (1980) 92-94
4. Blair A., and Fraumeni J.F. Geographic patterns of prostate cancer in the United States. J. Natl. Cancer Inst. 61 (1979) 1379-1384
5. Boice Jr. J.D., and Miller R.W. Childhood and adult cancer after intrauterine exposure to ionizing radiation. Teratology 59 (1999) 227-233
6. Bosland M.C. The role of steroid hormones in prostate carcinogenesis. J. Natl. Cancer Inst. Monographs 27 (2000) 39-66
7. Bourguet W., Ruff M., Chambon P., Gronemeyer H., and Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 375 (1995) 377-382
8. Brama M., Gnessi L., Basciani S., Cerulli N., Politi L., Spera G., Mariani S., Cherubini S., d'Abusco A.S., Scandurra R., and Migliaccio S. Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism. Mol. Cell. Endocrinol. 264 (2007) 102-108
9. Brooks S.C., Locke E.R., and Soule H.D. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J. Biol. Chem. 248 (1973) 6251-6253
10. Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J., and Carlquist M. Molecular basis of agonism and antagonism in the estrogen receptor. Nature 389 (1997) 753-758
11. Cantor K.P., Stewart P.A., Brinton L.A., and Dosemeci M. Occupational exposures and female breast cancer mortality in the United States. J. Occup. Med. 37 (1994) 336-348
12. Choe S.Y., Kim S.J., Kim H.G., Lee J.H., Choi Y., Lee H., and Kim Y. Evaluation of estrogenicity of major heavy metals. Sci. Total Environ. 312 (2003) 15-21
13. Colborn T., von Saal F.S., and Soto A.M. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ. Health Perspect. 101 (1993) 378-384
14. Cowley S.M., Hoare S., Mosselman S., and Parker M.G. Estrogen receptors alpha and beta form heterodimers on DNA. J. Biol. Chem. 272 (1997) 19858-19862
15. Darbre P.D. Aluminium, antiperspirants and breast cancer. J. Inorg. Biochem. 99 (2005) 1912-1919
16. Donovan M.P., Schein L.G., and Thomas J.A. Inhibition of AR interaction in mouse prostate gland cytosol by divalent metal ions. Mol. Pharmacol. 17 (1979) 156-162
17. Dorgan J.F., Baer D.J., Albert P.S., Judd J.T., Brown E.D., Corle D.K., Campbell W.S., Hartman T.J., Tejpar A.A., Clevidence B.A., Giffen C.A., Chandler D.W., Stanczyk F.Z., and Taylor P.R. Serum hormones and the alcohol-breast cancer association in postmenopausal women. J. Natl. Cancer Inst. 93 (2001) 710-715
18. Dubrow R., and Wegman D.H. Cancer and occupation in Massachusetts: a death certificate study. Am. J. Ind. Med. 6 (1984) 207-230
19. Egea P.F., Klaholz B.P., and Moras D. Ligand-protein interactions in nuclear receptors of hormones. FEBS Lett. 476 (2000) 62-67
20. Egea P.F., Mitschler A., Rochel N., Ruff M., Chambon P., and Moras D. Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. EMBO J. 19 (2000) 2592-2601
21. Elghany N.A., Schumacher M.C., Slattery M.L., West D.W., and Lee J.S. Occupation, cadmium exposure, and prostate cancer. Epidemiology 1 (1990) 107-115
22. Feigelson H.S., Jonas C.R., Teras L.R., Thun M.J., and Calle E.E. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol. Biomark. Prev. 13 (2004) 220-224
23. Feuer E.J., Wun L.M., Boring C.C., Flanders W.D., Timmel M.J., and Tong T. The lifetime risk of developing breast cancer. J. Natl. Cancer Inst. 85 (1993) 892-897
24. Garcia-Morales P., Saceda M., Kenney N., Kim N., Salomon D.S., Gottardis M.M., Solomon H.B., Sholler P.F., Jordan V.C., and Martin M.B. Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells. J. Biol. Chem. 269 (1994) 16896-16901
25. Hankinson S.E., Willett W.C., Manson J.E., Colditz G.A., Hunter D.J., Spiegelman D., Barbieri R.L., and Speizer F.E. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 90 (1998) 1292-1299
26. Han S.J., Lonard D.M., and O'Malley B.W. Multi-modulation of nuclear receptor coactivators through posttranslational modifications. Trends Endocrinol. Metab. 20 (2009) 8-15
27. Henderson B.E., Ross R.K., Judd H.L., Krailo M.D., and Pike M.C. Do regular ovulatory cycles increase breast cancer risk?. Cancer 56 (1985) 1206
28. Hoover R., Gray Sr. L.A., Cole P., and MacMahon B. Menopausal estrogens and breast cancer. N. Engl. J. Med. 295 (1976) 401-405
29. Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman Z.L., Friedman M., Papsidero L., Kim U., Chai L.S., Kakati S., Arya S.K., and Sandberg A.A. The LNCaP cell line - a new model for studies on human prostate carcinoma. Prog. Lin. Biol. Res. 37 (1980) 115-132
30. Johnson M.D., Kenney N., Stoica A., Hilakivi-Clarke L., Singh B., Chepko G., Clarke R., Sholler P.F., Lirio A.A., Foss C., Reiter R., Trock B., Palk S., and Martin M.B. Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland. Nat. Med. 9 (2003) 1081-1084
31. Kampert J.B., Whittemore A.S., and Paffenbarger Jr. R.S. Combined effect of child-bearing, menstrual events, and body size on age-specific breast cancer risk. Am. J. Epidemiol. 128 (1988) 962-979
32. Kipling M.D., and Waterhouse J.A.H. Cadmium and prostatic carcinoma. Lancet 28 (1967) 199-204
33. Krust A., Green S., Argos P., Kumar V., Walter P., Bornert J.M., and Chambon P. The chicken oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptors. EMBO J. 5 (1986) 891-897
34. Kumar V., Green S., Stack G., Berry M., Jin J.R., and Chambon P. Functional domains of the human estrogen receptor. Cell 51 (1987) 941-951
35. Land C.E. Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer. JAMA 274 (1995) 402-407
36. Lemen R.A., Lee J.S., Wagoner J.K., and Blefer H.P. Cancer mortality among cadmium production workers. Ann. N.Y. Acad. Sci. 271 (1976) 273-279
37. Lippman M.E. Endocrine responsive cancers of man. In: Williams R.H. (Ed). Textbook of Endocrinology (1985), W.B.Saunders, Philadelphia 1309-1326
38. Liu Z., Yu X., and Shaikh Z.A. Rapid activation of ERK1/2 and AKT in human breast cancer cells by cadmium. Toxicol. Appl. Pharmacol. 228 (2008) 286-294
39. Lu J., and Danielsen M. Differential regulation of androgen and glucocorticoid receptors by retinoblastoma protein. J. Biol. Chem. 273 (1998) 31528-31533
40. MacMahon B., Cole P., and Brown J. Etiology of human breast cancer: a review. J. Natl. Cancer Inst. 50 (1973) 21
41. Madigan M.P., Ziegler R.G., Benichou J., Byrne C., and Hoover R.N. Proportion of breast cancer cases in the United States explained by well-established risk factors. J. Natl. Cancer Inst. 87 (1995) 1681-1685
42. Martinez-Campa C., Alonso-Gonzalez C., Mediavilla M.D., Cos S., Gonzalez A., Ramos S., and Sanchez-Barcelo E.J. Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. J. Pineal. Res. 40 (2006) 291-296
43. Martin M.B., Voeller H.J., Gelmann E.P., Lu J., Stoica E.G., Hebert E.J., Reter R., Singh B., Danielsen M., Pentecost E., and Stocia A. Role of cadmium in the regulation of AR gene expression and activity. Endocrinology 143 (2002) 263-275
44. Martin M.B., Reiter R., Pham T., Avellanet Y.R., Camara J., Lahm M., Pentecost E., Pratap K., Gilmore B., Divekar S., Dagata R.S., Bull J., and Stoica A. Estrogen like activity of metals in MCF-7 breast cancer cells. Endocrinology 144 (2003) 2425-2436
45. Matias P.M., Donner P., Coelho R., Thomaz M., Peixoto C., Macedo S., Otto N., Joschko S., Scholz P., Wegg A., Basler S., Schafer M., Egner U., and Carrondo M.A. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 275 (2000) 26164-26171
46. McElroy J.A., Shafer M.M., Trentham-Dietz A., Hampton J.M., and Newcomb P.A. Cadmium exposure and breast cancer risk. J. Natl. Cancer Inst. 98 (2006) 869-873
47. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
48. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., and Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395 (1998) 137-143
49. Peeters P.H., Keinan-Boker L., van der Schouw Y.T., and Grobbee D.E. Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res. Treat. 77 (2003) 171-183
50. Pettersson K., and Gustafsson J.A. Role of estrogen receptor beta in estrogen action. Annu. Rev. Physiol. 63 (2001) 165-192
51. Pettersson K., Delaunay F., and Gustafsson J.A. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 19 (2000) 4970-4978
52. Pike M.C., Henderson B.E., Casagrande J.T., Rosario I., and Gray G.E. Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br. J. Cancer 43 (1981) 72
53. Potts C.L. Cadmium proteinuria-the health of battery workers exposed to cadmium oxide dust. Ann. Occup. Hyg. 8 (1965) 55-61
54. Raymond-Whish S., Mayer L.P., O'Neal T., Martinez A., Sellers M.A., Christian P.J., Marion S.L., Begay C., Propper C.R., Hoyer P.B., and Dyer C.A. Drinking water with uranium below the U.S. EPA water standard causes estrogen receptor-dependent responses in female mice. Environ. Health Perspect. 115 (2007) 1711-1716
55. Renaud J.P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., and Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 378 (1996) 681-689
56. Richie R.C., and Swanson J.O. Breast cancer: a review of the literature. J. Insur. Med. 35 (2003) 85-101
57. Rulisek L., and Vondrasek J. Coordination geometries of selected transition metal ions (Co2+, Ni2+, Cu2+, Zn2+, Cd2+, and Hg2+) in metalloproteins. J. Inorganic. Biochem. 71 (1998) 115-127
58. Sack J.S., Kish K.F., Wang C., Attar R.M., Kiefer S.E., An Y., Wu G.Y., Scheffler J.E., Salvati M.E., Krystek Jr. S.R., Weinmann R., and Einspahr H.M. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 4904-4909
59. Safe S. Endocrine disruptors and human health: is there a problem. Toxicology 205 (2004) 3-10
60. Safe S.H. Environmental and dietary estrogens and human health: is there a problem?. Environ. Health Perspect. 103 (1995) 346-351
61. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., and Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
62. Stoica A., Katzenellenbogen B.S., and Martin M.B. Activation of estrogen receptor-alpha by the heavy metal cadmium. Mol. Endocrinol. 14 (2000) 545-553
63. Stoica A., Pentecost E., and Martin M.B. Effect of arsenite on estrogen receptor-a expression and activity in MCF-7 breast cancer cells. Endocrinology 141 (2000) 3595-3602
64. Stoica A., Pentecost E., and Martin M.B. Effects of selenite on estrogen receptor-a expression and activity in MCF-7 breast cancer cells. J. Cell. Biochem. 79 (2000) 282-292
65. Tanenbaum D.M., Wang Y., Williams S.P., and Sigler P.B. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domain. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 5998-6003
66. Tokunaga M., Land C.E., Yamamoto T., Asano M., Tokuoka S., Ezaki H., and Nishimori I. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1980. Radiat. Res. 112 (1987) 243-272
67. Toniolo P.G., Levitz M., Zeleniuch-Jacquotte A., Banerjee S., Koenig K.L., Shore R.E., Strax P., and Pasternack B.S. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J. Natl. Cancer Inst. 87 (1995) 190-197
68. Ursin G., Bernstein L., and Pike M.C. Breast cancer. In: Doll R., Fraumeni J.F., and Muir C.S. (Eds). Cancer Surveys (1994), Cold Spring Harbor Laboratory Press, Plainview, NY 241-264
69. Veselik D.J., Divekar S., Dakshanamurthy S., Storchan G.B., Turner J.M., Graham K.L., Huang L., Stoica A., and Martin M.B. Activation of estrogen receptor-alpha by the anion nitrite. Cancer Res. 68 (2008) 3950-3958
70. Visser A.J., and Deklerk J.N. The effect of dietary cadmium on prostate growth. Trans. Am. Assoc. Genito-Urinary Surg. 70 (1979) 66-68
71. Waalkes M.P., and Rehm S. Cadmium and prostate cancer. J. Toxicol. Environ. Health 43 (1994) 251-269
72. Wagner R.L., Apriletti J.W., McGrath M.E., West B.L., Baxter J.D., and Fletterick R.J. A structural role for hormone in the thyroid hormone receptor. Nature 378 (1995) 690-697
73. Webber M.M. Selenium prevents the growth stimulatory effects of cadmium on human prostate epithelium. Biochem. Biophy. Res. Comm. 127 (1985) 871-877
74. West D.W., Slattery M.L., Robinson L.M., French T.K., and Mahoney A.W. Adult dietery intake and prostate cancer risk in Utah. A case-control study with special emphasis on aggressive tumors. Cancer Causes Control 2 (1991) 85-94
75. Williams S.P., and Sigler P.B. Atomic structure of progesterone complexed with its receptor. Nature 393 (1998) 392-396
76. Wilson V.S., Bobseine K., and Gray Jr. L.E. Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists. Toxicol. Sci. 81 (2004) 69-77
77. Wurtz J.M., Bourguet W., Renaud J.P., Vivat V., Chambon P., Moras D., and Gronemeyer H. A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. 3 (1996) 87-94
78. Yong L.C., Brown C.C., Schatzkin A., and Schairer C. Prospective study of relative weight and risk of breast cancer: the Breast Cancer Detection Demonstration Project follow-up study, 1979 to 1987-1989. Am. J. Epidemiol. 143 (1996) 985-995